TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
7/13/23 17:15 | 7/11/23 | EVLO | Evelo Biosciences, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Flagship Ventures Fund IV General Partner LLC | MA | T | P | 12,500 | 2.31 | 0 | 5,411 | 215 | 7,933 | I | |||||||||||||||
10/17/22 16:42 | 10/13/22 | AXLA | Axcella Health Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Flagship Ventures Fund IV General Partner LLC | MA | T | P | 17,029 | 1.64 | 0 | 10,384 | 55 | 29,252 | I | |||||||||||||||
6/1/22 19:00 | 5/27/22 | EVLO | Evelo Biosciences, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Flagship Ventures Fund IV General Partner LLC | MA | T | P | 40,000 | 1.46 | 0 | 27,397 | 119 | 50,427 | I | |||||||||||||||
3/18/22 08:30 | 3/16/22 | AXLA | Axcella Health Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Flagship Ventures Fund IV General Partner LLC | MA | T | P | 12,070 | 1.91 | 0 | 6,319 | 50 | 18,868 | I |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |